Skip to main content

Table 1 Clinical characteristic of HCC patients and corresponding relationship with CTCs before treatment (n = 21)

From: The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma

Clinical characteristics Average CTC numbers Average CTC numbers
Total EpCam Vimentin HSPG HSPG/total HSPG serial (%) GPC3 GPC3/total HSPG serial (%)
Age, years
 > 50 8 5 3 2 10.00 3 15.00
 ≤ 50 10 5 5 2 11.11 2 11.11
Gender
 Male 9 5 4 2 10.53 2 10.53
 Female 10 6 3 2 11.11 2 11.11
Number of tumors
 Singleton 9 4 4 2 10.00 3 15.00
 Multiple 9 5 4 2 9.09 4 18.18
AFP
 > 300 ng/mL 12 6 6 2 8.70 3 13.04
 ≤ 300 ng/mL 8 4 3 2 9.52 3 14.29
Tumor size (cm)
 > 5 cm 9 4 4 2 10.00 3 15.00
 ≤ 5 cm 9 5 4 2 10.00 3 15.00
BCLC stage
 0 7 4 3 2 15.38 0 0.00
 A 8 5 3 2 10.00 3 15.00
 B 8 3 5 3 11.11 5 18.52
 C 12 6 6 2 9.09 3 13.64
PIVKA
 > 70 ng/ml 9 5 4 2 9.52 3 14.29
 ≤ 70 ng/ml 8 5 3 3 15.00 4 20.00
Large vessel tumor thrombus
 Yes 12 6 6 2 9.09 3 13.64
 Non 8 4 3 2 9.52 3 14.29
MVI
 = M0 8 5 3 2 10.00 3 15.00
 ≠ M0 9 5 5 2 9.52 3 14.29
  1. HSPG serial of immunoliposomes contain IMLs constructed with antibody of GPC1, GPC3, SDC1, SDC2, and common antibody of HSPG
  2. CTC circulating tumor cell, HSPG heparan sulfate proteoglycans, AFP alpha-fetoprotein, PIVKA protein induced by vitamin K absence, CEA carcinoembryonic antigen
\